Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Issued Date
2024-01-01
Resource Type
ISSN
02692813
eISSN
13652036
Scopus ID
2-s2.0-85205887843
Journal Title
Alimentary Pharmacology and Therapeutics
Rights Holder(s)
SCOPUS
Bibliographic Citation
Alimentary Pharmacology and Therapeutics (2024)
Suggested Citation
Leong R., Sakiris A., Arzivian A., Chetwood J., Chaemsupaphan T., Sparrow M., Kamm M., Kariayawasam V. Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases. Alimentary Pharmacology and Therapeutics (2024). doi:10.1111/apt.18318 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/101640
Title
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential. Aims: To create a comprehensive set of statements on assessment procedures and vaccinations before starting monoclonal antibodies, Janus kinase (JAK) inhibitors or sphingosine-1-phosphate (S1P) modulators for IBD. Methods: We examined literature, guidelines and drug product information regarding vaccination and assessment recommendations for initiating advanced IBD therapies. Using a modified Delphi approach, delegates voted anonymously on the acceptability of these statements prior to and following consensus discussion. Results: We developed eight statements on the domains of infectious diseases screening, vaccinations and assessments prior to commencing JAK inhibitors and S1P modulators. Six statements received agreement. Pre-advanced therapy screening for infectious diseases was established, and the vaccination protocol was revised. Malignancy, cardiovascular and thromboembolic risk assessments are necessary before initiating JAK inhibitors. Those starting S1P modulators need cardiac and ophthalmic assessments. Conclusions: These consensus statements combine vaccination and assessments on the currently available advanced therapies for IBD as a single comprehensive document that may reduce IBD complications associated with use of advanced therapies. Knowledge gaps identified during the consensus process will provide further research opportunities.